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Optogenetic Treatment of Blindness
By Mara Kaspers

35

W

e are moving to a
world where a single
injection into the
eye can restore vision of the blind.
In September of 2018, a patient
suffering from retinitis pigmentosa,
a common disease resulting in
complete blindness, was the first
to receive optogenetic treatment
designed to restore their vision.
This patient at the UPMC Eye
Center in Pittsburgh is part of a
pioneer clinical trial carried out
by biopharma company GenSight
Biologics. What are some of the
recent developments in molecular
biology that have made this therapy
possible? What is so novel about
this technique and what are some
things to consider before starting
large scale implementation?

What Is
Optogenetics?
Optogenetics is a very young
lab technique first developed in
2005 by a group of researchers
at
Stanford
University
and
spearheaded by Dr. Karl Deisseroth.
The technique allows researchers
to control neurons, the building
blocks of the brain, with the use of
light by changing the genetic code,
or blueprint, of a living organism.
Dr. Deisseroth and his team were
inspired by a certain type of algae
that has the ability to detect light
with an endogenous light-sensitive
protein called Channelrhodopsin-2
(ChR2). These algae use this
information to swim towards the
light, which is beneficial for certain
biological processes and like all
proteins, Channelrhodopsin-2 is
coded for in the algae’s DNA. Dr.
Deisseroth and his colleagues
were successful in extracting that
exact piece of DNA and placing
it into neurons of living organisms
like mice and eventually people.
When expressed in neurons, these
algae-derived
opsins
operate
much like a switch, allowing the
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researcher to activate or silence
the neurons simply by shining
light on them. This switch is very
fast and can change brain activity
within milliseconds. This technique
was so innovative and promising
for the neuroscientific field that it
was awarded with “Method of the
Year” by Nature Methods in 2010
and received “Breakthrough of the
Decade” by Science BotD in 2013.
However, for medical application in
people, turning all neurons in the
brain on and off at the same time
would not be helpful. Rather, we
want to be able to control certain
groups of neurons in certain parts
of the brain selectively. Luckily,
we have a lot of knowledge about
the genetic blueprints of mice,
humans, and many other organisms
so we can choose which type of
neuron and where in the brain
this biological switch should be
produced.
It didn’t take long for
researchers to use this extremely
exciting technique in people as
optogenetics has now been used
to expand our understanding
of brain mechanisms involved
in
neurological
conditions
like
depression,
Parkinson’s,
Schizophrenia, autism, aggression,
and addiction. This research then
quickly developed into the use of
optogenetics in clinical treatment
of these disorders. However, since
the opsins need direct light to
activate a cell, treatment of these
disorders would require people
to walk around with a power cord
through their skull, emitting light
directly on their brain. While this
is certainly not impossible and
has been successful in other living
organisms like mice, it is not the
ideal starting place. An easier first
step into optogenetic treatment of
human diseases is targeting neurons
that are more easily accessible with
light, like the ones found in your
eye. When produced in neurons
in the eye, the switch is easily

accessible for light and treatment
would be minimally invasive. This
is why patients suffering from
genetically determined blindness,
like patient Pittsburgh, are the
first to receive this cutting-edge
optogenetic treatment, which will
have an incredible impact on the
neuroscientific community if proven
successful.

Restoring Vision of
the Blind
Optogenetic
treatment
provides hope for over 1.5 million
people across the world that suffer
from degenerative retinal diseases
like retinitis pigmentosa. Retinitis
pigmentosa is a heritable disease
causing the first line of cells in
the eyes, the photoreceptors, to
die. Photoreceptors are the only
light-sensitive cells in the eye and
degeneration therefore results in
complete blindness. Rosalinda
Barrero, a retinitis pigmentosa
patient advocate, recalls not
wanting to go out for trick or
treating when she was younger
because it was already hard for
her to see in the dark. At a board
meeting of the California Institute
for Regenerative Medicine, her
husband shares that they met
because she accidently got into his
car instead of her date’s. This funny
anecdote of the beginning of their
relationship eludes to the fact that
by the time she was in her twenties,
Rosalinda had lost nearly all vision.
She is now a mother of three and
has never been able to see her
husband or kids. The family shares
their excitement about optogenetic
research and the beginning of the
clinical trials.
As illustrated by Rosalinda’s
story, onset of the retinitis
pigmentosa often begins during
childhood and develops into early
adulthood. It often starts with loss
of peripheral vision as the sides
of the visual field become blurry.
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Within the span of a couple years,
this loss of vision will gradually
expand to the middle of the visual
field until all photoreceptors are
lost and no amount of light can
elicit visual perception. While this
first layer of crucial photoreceptors
will be completely lost over time,
the other cell layers of the retina
remain intact and provide a perfect
target for optogenetic treatment.
By making the remaining healthy
cells produce the extracted algae
opsins, researchers can restore the
eye’s sensitivity to light. This way,
most of the visual system’s healthy
wiring remains intact and the patient
should be able to produce a picture
of the world by simply “skipping”
the dead photoreceptors.
The
Pittsburgh
patient
received one injection into one of
their eyes. This injection contained
the algae DNA and targeted the
retinal ganglion cells, the cell layer
following the photoreceptors,
to
express
channelrhodopsin
proteins. The newly engineered
light-sensitive
ganglion
cells
should now cause the visual
pathway to be activated when
exposed to light and hopefully
restore some vision of the patient
(Figure 1). However, this therapy
will not restore vision perfectly
because channelrhodopsins are
not as complex as photoreceptors.
There are many photoreceptor
functions that these opsins simply
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read the visual input of the world
and translate it into a code that the
brain can understand. The most
successful microchip treatment
allowed blind patients to read
about 10 words per minute, which
is slow compared to the healthy
speed of 200 words a minute.
Nevertheless, this was a great
success, but Dr. Sahel also explains
how there is a limit to the restorative
abilities of these implants. With
current technological limitations,
the chips will never be able to
produce a resolution resembling
healthy vision. In other words, the
restored vision will always be blurry.
Therefore, GenSight decided to
switch to a biological technique
and use optogenetics to:

cannot mimic like adapting to
different light intensities or optimal
detection of contrast. Therefore,
we cannot expect vision to be
perfectly restored, but hopefully
the treatment will allow
patients to observe large
“Transform any type of
objects and move through
the world independently remaining neuron in the retina
again. Sean Ainsworth, into a photoreceptor”
CEO
of
biopharma
company RetroSense says
he hopes the patients will be able to
This was the beginning of the
“see tables and chairs” and maybe current clinical trials that patient
even read large letters with the help Pittsburgh is a part of.
of light-enhancing goggles. The
While RetroSense has yet
neuroscience community is waiting to have published any results
in suspense as these first transgenic regarding their first trials, GenSight
patients are being assessed for has confirmed the safety of the first
safety. If proven successful and treated patients in three centers
safe, the implications for the future across the United States, United
of brain medicine are incredibly Kingdom, and France in May of
promising.
2019. Bernard Gilly, another cofounder of GenSight, is pleased
to be able to move forward to the
second phase of their trials and
Two
major
companies, says that they “look forward to
GenSight and RetroSense, are confirming the safety of GS030 at
dedicated to advancing the field higher doses and to demonstrate
of optogenetic treatment of efficacy in restoring useful visual
blindness and are currently running functions in RP patients”. They
clinical trials studying a total of have since injected the next three
39 patients suffering from retinitis patients with a higher dose of the
pigmentosa,. Dr. Jose Sahel, co- treatment (GS030) and hope to
founder of GenSight, explains how release their preliminary results in
they are already able to partially late 2020. Since human testing is
restore impared vision with the still in the safety testing phase and
use of microchips placed in the no treatment efficacy assessments
back of the eye. These microchips have been made, we are basing
work much like a scanner as they

Clinical Trials
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our excitement for possible vision
restoration on preliminary animal
research. What are the findings that
are driving these human trials?

Preclinical Research
Mice lend themselves well for
initial testing of genetic treatment
as we know a lot about their
genetic blueprint and have some
widely applied ways to test their
behavior. About 8 years ago, a
team of researchers located across
the United States collaborated to
achieve one of the first successful
optogenetic vision restorations in
blind mice. After treatment, they
compared how long it took for
healthy, blind, and treated blind
mice to find a platform in a maze
of water. As you might expect, the
healthy mice were rather quick
to find the platform, whereas
the blind mice were swimming
around seemingly aimlessly before
accidentally stumbling upon it.
What was amazing about this study
is that the blind mice that were
treated with optogenetics were just
as fast as the healthy mice to find

the platform, suggesting that their
vision was restored to the quality
of healthy mice, and the treatment
worked. In a TED Talk around that
same time, a leader in the field, Dr.
Ed Boyden, shares his excitement
about this particular study and
says that the results bode hope for
potential therapeutic application
in people. The data presented in
this study were monumental for the
current clinical trials on optogenetic
treatment of blindness.
These findings were confirmed
by many other behavioral studies
of mice in the years after, among
which were research groups in
France associated with GenSight.
One GenSight study tested the
efficacy of optogenetic treatment
by comparing how long it took for
healthy, blind, and treated mice
to respond to light at the end of
a tube and return to the safety of
darkness. Again, the researchers
were pleasantly surprised to see
the treated mice to behave in the
exact same way as their healthy
counterparts and run away from
the light as quickly as possible,

suggesting the treatment was
effective.
While these results were
important and exciting, preliminary
research had to be done on human
retinas to further strengthen the
translatability of the therapy. This
led the GenSight groups in Paris
to test optogenetics in human and
monkey retinas. They were able to
successfully make the remaining
healthy cells in the retina produce
channelrhodopsin proteins and
found that the cells were activated
in response to light. This data
showed efficacy and safety of
optogenetic treatment in deceased
human retinas. This was the last bit
of data necessary for the human
clinical trials to be launched and
the first patients to be enrolled
in the GenSight study. If this
treatment shows to be safe and
effective in people suffering from
retinitis pigmentosa, it will have
great implications for optogenetic
treatment of other brain disorders
including epilepsy, post-traumatic
stress disorder, anxiety, depression,
and many more.

Figure 1. Infographic illustrating optogenetic treatment of an eye suffering from retinitis pigmentosa.
”Cataract”, DNA”, “Retina” by Servier Medical Art by Servier (CC BY 3.0.).“Spectrum” by Megabeckett27 from Wikimedia (CC BY-SA 3.0). Graph was
adapted from figure 6D from Sengupta, et al. (2016)..Adapted by Mara Kaspers.

38

SCIENTIFIC KENYON
© 2017 Lim and LeDue (CC BY 4.0)

Optogenetics Beyond
Blindness
People like Dr. Deisseroth
and Dr. Boyden let their minds
wander far past optogenetic
treatment of blindness. There are
endless research and treatment
opportunities
that
this
lab
technique introduces in the world
of neuroscience that has and will
change the way we approach
modern questions of the brain.
Imagine all the things you can
explore by having the ability to
activate and silence whole parts
of the brain, or even types of brain
cells, within milliseconds. This ultraprecise control of neurons provides
hope for treating previously
untreatable disorders including
post-traumatic stress disorder
(PTSD) or epilepsy.
PTSD is characterized by high
levels of anxiety and fear related
to a memory. Dr. Boyden and his
team were able to reverse this
type of fearful memory in a mouse
model using optogenetics. They
had induced a model for PTSD into
the mouse by introducing a shock
every time a tone was played. As
a result, the mouse would freeze,
a behavior expression of fear,
every time the tone was played. To
treat the mouse of this memory39

related fear, they activated the
prefrontal cortex, often referred
to as the cognitive center of the
brain, by shining light on the newly
expressed channelrhodopsin. By
activating the prefrontal cortex
simultaneously with playing the
tone, the fear of the tone was
reversed, and the mouse was cured
of its induced PTSD within only 10
minutes.
Another
application
that
Dr. Boyden mentions with great
excitement is the treatment of
epilepsy. A symptom of epilepsy is
greater risk of seizures, which are
characterized by overactive neurons
and sporadic brain activity. Seizures
can have major effects on the brain
and leave permanent damage if
not controlled quickly enough.
As an optogenetic treatment, we
could make neurons in the brain
express a different type of lightsensitive opsin which silences cells
instead of activating them. During
a seizure, you would expose the
brain to light, causing the switches
to turn the cells off and thus reduce
brain activity and restore healthy
firing patterns.
As
mentioned
before,
treatment of PTSD and epilepsy
are just the tip of the iceberg of all
possible optogenetic applications
in medicine. However, while the

current clinical trials and novel data
are promising, they do not come
without risk and there are various
ethical considerations to be made
before wide application is possible.
Optogenetic treatment involves
editing the human genome and
contributes to the transhumanism
movement as we introduce
exogenous DNA into people. This
brings up the ethics of clinical
testing, a more philosophical
debate of free will, and questions
about how comfortable we are
disrupting human evolution on a
large scale.

OptogenEthics
For obvious reasons, people
like Dr. Deisseroth and Dr. Boyden
refrain from discussing the ethical
implications of gene editing and
prefer to focus on the medical
benefits. However, editing the
DNA of a person to treat a disease
remains controversial and should
be discussed as the first clinical
trials are being conducted.
The primary goal of phase
1 testing in the GenSight and
RetroSense clinical trials is safety
rather than efficacy. This brings up
an interesting ethical debate about
phase 1 human trials and riskbenefit ratio for the patient. If the
researchers are only assessing safety
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and not the medical benefit, what is In the case of treating blindness,
in it for the patient? And who really however, the aim of the treatment
benefits from the research? The risk- is much different. The treatment is
benefit ratio seems disadvantaged designed to improve the quality of
for patients as they are receiving life, but adverse outcomes of the
an irreversible treatment that will treatment could quickly outweigh
only be assessed for safety. On top the potential benefits.
Optogenetic
treatment
of that, participants are excluded
from any future innovative, perhaps also brings a more philosophical
more effective, therapeutic trials, question to the table. Optogenetic
increasing the individual risk of headlines often include phrases
enrolling in these trials even more. like “how to take over a brain” or
Including efficacy in phase 1 clinical “external control of the brain”.
trials has long been a debate in While these statements speak to the
the medical field and there are incredible power of optogenetics, it
many cancer treatment trials that also introduces an ethical dilemma
have already accepted the efficacy of free will. You might argue that
endpoint as a norm1. The highly externally controlling the brain can
invasive aspect of optogenetic threaten human autonomy and
identity by questioning:
treatment
and
skewed
risk-benefit
ratio are important
“What becomes of the
points
of
debate
individual, whose brain can now be
when discussing the
manipulated via remote control?”11
future of the current
optogenetic clinical
Are these patients potentially
trials.
losing
a part of their autonomy and
Another interesting aspect of
the optogenetic trials on blindness identity? Will introduction of algae
is the nature of the disease. Since proteins into a human brain have
blindness is not a terminal illness, unforeseen effects on the psyche?
this treatment is considered to be a Are treated patients under too
non-life-preservative intervention. much control of the environment?
Some argue that patients suffering With so little knowledge about
from a terminal illness might only how the mind is formed from our
have one shot at a potential new biological brain structures and
treatment, therefore increasing interaction with the world, these
the ethical acceptability of phase 1 are questions worth asking.
Finally,
altering
human
safety testing in these individuals.

genomes with DNA derived from
a different organism, could lead
to unpredictable effects on human
evolution. Richard Dawkins, author
of The Selfish Gene, argues that
our genetic building blocks, our
DNA, are the oldest driver of
human evolution. Genes have been
passed on for many generations
and we are, as Dawkins argues,
mere transporters of the genes
through time. This is how human
evolution has always worked,
but with current developments
in cheap DNA sequencing, gene
editing techniques like CRISPR,
and genetic therapeutics like
optogenetics, we are at risk of
disrupting the natural process of
evolution. This could have major
effects on humankind that we
simply cannot predict. As we enter
an age where transhumanism is a
rapidly growing field, these are
topics necessary to discuss before
moving forward with novel genetic
therapies like optogenetics.
Nevertheless, these clinical
trials are a source of hope for
families like patient Pittsburgh’s
and Rosalinda’s. About a decade
ago, their doctors would have
nothing to offer them, no hope
for improvement, just acceptance
of living in the dark for the rest
of their lives. Now, with the rapid
improvement
of
optogenetic
treatment, there is light at the end
of the tunnel again.

REFERENCES
1. Gilbert, F., Harris, A., Kapsa, A. Controlling Brain Cells With
Light: Ethical Considerations for Optogenetic Clinical Trials.
AJOB Neuroscience, 5(3), 3-11 (2014).
2. California Institute for Regenerative Medicine. A Stem
Cell-Based Therapy for Retinitis Pigmentosa: The Patient’s
Perspective. YouTube (2014).
3. GenSight Biologics. Dose-Escalation Study to Evaluate
the Safety and Tolerability of GS030 in Subjects With Retinitis
Pigmentosa. ClinicalTrials.gov (2018).
4. Allergan. RST-001 Phase I/II Trial for Advanced Retinitis
Pigmentosa. ClinicalTrials.gov (2015).
5. cmurobotics. RI Seminar: José Alain Sahel, MD : ...Artificial
Vision, Artificial Retina, Optogenetics. YouTube (2017).
6. GenSight Biologics Announces Positive Data Safety
Monitoring Board Review and Continuation of PIONEER Phase

I/II Clinical Trial of GS030 Combining Gene Therapy and
Optogenetics for the Treatment of Retinitis Pigmentosa. GenSight
Biologics (2019).
7. Doroudchi, M. et al. Virally delivered channelrhodopsin-2
safely and effectively restores visual function in multiple mouse
models of blindness. Mol Ther, 19(7), 1220-1229 (2011).
8. TED. Ed Boyden: A Light Switch for Neurons. YouTube (2011).
9. Mace, E. et al. Targeting channelrhodopsin-2 to ON-bipolar
cells with vitreally administered AAV Restores ON and OFF visual
responses in blind mice. Mol Ther, 23(1), 7-16 (2015).
10. Sengupta, A. et al. Red-shifted channelrhodopsin stimulation
restores light responses in blind mice, macaque retina, and
human retina. EMBO Mol Med, 8(11), 1248-1264 (2016).
11. Starkman, R. Optogenetics: A novel technology with
questions old and new. Huffington Post (2012).
40

